Cytori Therapeutics (NASDAQ:CYTX) and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) formed collaboration to develop adipose-derived stem and regenerative cell-based treatments for ischemic stroke. The Fraunhofer Society will commit $425,000 over two years in support to Cytori’s already planned research and development.

The goal of the collaboration is to advance adipose-derived stem and regenerative cells into clinical trials for ischemic stroke. The underlying damage in ischemic stroke is brought about by a loss of blood flow to the brain. Because adipose-derived stem and regenerative cells have been shown to improve tissue outcome during injury resulting from a reduction in blood flow, it is believed that these cells could represent a novel approach for reducing stroke-induced damage.

“Our interest in ischemic stroke is based on several factors,” said Kai Pinkernell, M.D., head of research for Cytori. “First, ischemic stroke represents a tremendous unmet medical need, whereby vascular blockages in the brain can result in loss of brain function. Second, because ischemic stroke is brought about by a loss of blood supply, we can apply what we already know about restoring blood flow and reducing tissue damage in cardiovascular disease. Third, timing is thought to be critical in the treatment of ischemic stroke and the Celution^® 800 System can make a patient’s own stem and regenerative cells available in real-time.”

The Fraunhofer Institute for Cell Therapy and Immunology will contribute their extensive scientific expertise in neural repair. “In combining the competencies of both partners in regenerative medicine, we will have the promising opportunity to develop a novel therapeutic strategy that might have the potential to beneficially influence functional recovery following ischemic stroke,” stated Dr. Johannes Boltze, head of the Neurorepair Research Group at Fraunhofer IZI. “For this, a step-wise experimental approach, including small and large animal studies adhering to the strict STAIR-criteria for stroke therapy development, will be utilized.” Cytori will contribute their knowledge in adipose-derived stem and regenerative cell biology as it relates to cardiovascular conditions. At the end of the two year term, Cytori will have the opportunity to advance the work into clinical trials and through to commercialization.

“This is the third grant within the last nine months for which we have the privilege to participate,” added Dr. Pinkernell.